Orexigen has submitted the Marketing Authorization Application for Contrave (naltrexone HCl/bupropion) to the European Medicines Agency. It is seeking approval...
Orexigen Therapeutics has resubmitted the Contrave (naltrexone sustained release (SR)/bupropion SR) New Drug Application to the FDA for weight loss...
Orexigen Therapeutics has announced that results of its IGNITE study of Contrave (bupropion and naltrexone) in obesity were published online...
In a paper published in The Journal of the American Medical Association (JAMA) results failed to show a cardiovascular benefit...
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary Takeda Pharmaceuticals U.S.A., Inc. and Orexigen Therapeutics, Inc. jointly announced that the...
Orexigen Therapeutics, Inc. announced successful results of the interim analysis of the LIGHT Study. Based on these results, the Company...
The FDA had requested a cardiovascular outcomes trial (CVOT) for Contrave (naltrexone HCl/bupropion)which the company had rejected. After a meeting...
The FDA had requested a cardiovascular outcomes trial (CVOT) for Contrave (naltrexone HCl/bupropion)which Orexigen had rejected. After a meeting with...
The LIGHT Study which the FDA had asked Orexigen not to disclose (but whose results were disclosed with a new...
Orexigen Therapeutics announced it has entered into an agreement with Takeda to acquire the United States rights to Contrave (naltrexone...